Navigation Links
Functional Imaging Supports Improved Cognition in Parkinson’s Disease Patients After REHACOP
Date:2/26/2017

Functional imaging data supports improved cognition in Parkinson’s disease (PD) patients after receiving cognitive rehabilitation, according to a study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress.

It is already known that cognitive rehabilitation programs are proven to be effective in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao et al., investigated structural and functional cerebral changes associated with cognitive rehabilitation in PD.

The study randomly divided 42 PD patients into a control and an experimental group, which received REHACOP, a cognitive rehabilitation program commonly used in psychosis and schizophrenia. The control group received only occupational activities. After treatment, the experimental group showed significant improvements in cognition and functional disability compared to the control group. While no significant structural changes were found between pre- and post-treatment, significant functional cerebral changes in PD patients was seen through resting-state and memory task-related fMRI.

Peter Schmidt, Senior Vice President and Chief Mission Officer at the National Parkinson Foundation, states, “Cognitive change is often the greatest concern for people with Parkinson’s, and we have seen in several studies that cognitive interventions can make a difference in patient outcomes. This study by Dr. Ibarretxe-Bilbao and colleagues takes this to the next step by providing insight into the mechanisms. While improving functional outcomes is our end goal, the best insight into how to optimize them usually comes from understanding the underlying biology. This analysis represents a significant contribution by linking the clinical benefits of a novel intervention to the changes in functional imaging.”

About the 1st Pan American Parkinson’s and Movement Disorders Congress: Meeting attendees gather to learn about the latest research findings and relevant issues in the field of Movement Disorders specific to North, Central and South America. Over 400 physicians and medical professionals will be able to view over 150 scientific abstracts submitted by clinicians from the Pan American region and throughout the world.

About the International Parkinson and Movement Disorder Society: The International Parkinson and Movement Disorder Society (MDS), an international society of over 5,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Read the full story at http://www.prweb.com/releases/2017/02/prweb14099706.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Ivalua Buyer V8 Launch: Many Functional Enhancements, Even Greater Setup Flexibility and a Simplified Interface
2. MDeverywhere Releases Practice 1st Version 3.2, Its Revolutionary Practice Management and Revenue Cycle Software Application, Including ICD-10 Functionality and Sandbox
3. New Infographic Explains Private Exchange Functionality and Future of Defined Contribution Funding Model
4. How to Get a Lean and Functional Body with the Lean Hybrid Muscle – Vinamy
5. Functional Printing Market (Substrate, Inks) Worth $13.79 Billion by 2020 - New Report by MarketsandMarkets
6. KORT Physical Therapists Now Utilizing the Selective Functional Movement Assessment to Develop a More Comprehensive Treatment Plan for Patients
7. KeeboMed Inc. Introduces Live Chat Functionality on Its Website UsedUltrasoundEquipment.com
8. Functional electrical stimulation improves neuronal regeneration after cerebral infarction
9. Functional nerve cells from skin cells
10. UCI researchers identify new functional roles on cell surfaces for estrogen
11. Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Plano, Texas (PRWEB) , ... May 26, 2017 , ... ... Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita ... , “We are pleased to be the first in Arkansas to introduce the ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: ... FAMILY-Our Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... used to say, he is "panther quick and leather tough." His love for others ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee Elementary ... number of critical issues to address before students could return to classes. , First, ... no disruption to class schedules. Second, the project had to comply with New Jersey ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
Breaking Medicine Technology: